Tuesday, January 31, 2023

Novopen smart pen will provide patient with information to self-manage their diabetes

Diabetes is one of those diseases that require greater involvement in its control, which is necessary to prevent medium and long-term complications, mainly cardiovascular. This control is by monitoring, in addition to a combination of balanced diet and physical exercise …

diabetes It is one of those diseases that need more of those who suffer from it. participation in the control of, is necessary to prevent complications in the medium and long term, primarily cardiovascular. This control includes the monitoring of glucose levels and the administration of insulin doses, in addition to a combination of a balanced diet and physical exercise, among other parameters involved in the proper control of this pathology.

companies Abbott why novo nordisk has taken a decisive step forward by integrating the two technological tools into a single support, a downloadable app on mobile phones that allows the measurement of blood glucose and insulin dosage to be customized. Thus, smart pen novopen Novo Nordisk integrates insulin dosing information into the app freestyle librelink From Abbott so people with diabetes can view it with information about their glucose levels and share it with health professionals.

We’re driven deep into a press conference Benedict’s EmileIn this regard, on Wednesday Dr Javier Ampudia, Endocrinology and Nutrition Specialist at the University Hospital of Valencia, juan francisco peran, President of the Spanish Diabetes Federation (FEDE), Ruth Gaspar, Diabetes Nurse Educator at La Paz University Hospital (Madrid), jose maria barranco, Abbott Director of Market Access and SalesAnd this Dr. A.S. francisco pazuelo, Medical Director of Novo Nordisk,


Dr. Javier Empudia, who has been practicing the profession for more than 25 years, puts glycemic control in the context of attendees. ,It is very important for diabetic patients Because of its poor glycemic control, glycemic load that persists over time is associated with complications“, he affirmed. In Spain, at the level of glycemic control, we are better than in the United Kingdom or Germany, but “have to improve“. He stressed that primary care has made a qualitative leap in the management of patients in recent years.”We have excellent insulin management equipment. We have good medicines and now we have technological advances“, Held.

The degree of glycemic control varies depending on the type of diabetes. In Spain, less than 30% of patients with type 1 diabetes have HbA1C values ​​below 7%, the standard threshold for the clinical definition of good metabolic control. This percentage rises to 62.5% in the case of people with type 2 diabetes.

Juan Francisco Perán provided sight to the patients. ,there is a very important change with the appearance of technological development, But we must differentiate between patients with type 1 diabetes and type 2 diabetes. This has helped empower Type 1 patients, but Type 2 diabetes patients still have many shortcomings, which have been largely forgotten. Primary care does not have the necessary time to devote to these patients.“, he lamented. He recalled that many complications can be avoided by promoting healthy lifestyle habits. Through his organization, he claims advances from public administration and conducts dissemination campaigns, so that patients can reach technological development within. Of course, “Everything is not going as fast as we all hope“, he said, pointing to the financing. For him, it is a great success that two big companies like Novo Nordisk and Abbott have come together. He recognized that the smart pen will fill the needs that so far have not been covered for patients. Has not been done and will bring security. This will provide the patient with information to self-manage their diabetes,

José María Barranco insisted that the implementation of the idea is essential. The collaboration between these two companies aims to improve patient’s life. Part of it is the sensor, which is small and easy to use. It is put on the arm and transmits the data to the mobile, and replaces the prick in the finger. The sensor measures every minute. And the information should be transmitted in a simple way. ,he has come to contribute improve quality of life, under control and facilitated diabetes education. We found a company like Novo Nordisk that has experience in pharmaceuticals“, he pointed, He further said that “This meeting adds a grain of sand to that expected improvement.,


For his part, Dr. Francisco Pazuelo insisted that he lacked a unified foot when the pharmacological treatment was administered. This used to be written in a notebook or by heart, and the patient can now see on the display that, for example, insulin has been administered and it relieves him of pain. The healthcare professional has a vision of glycemic control and can make decisions Regarding treatment.

Ruth Gaspar asked the audience if they remembered what they had eaten two days prior, to show that chronicity can be very hard. According to some studies, a person with diabetes may have to make up to 40 additional decisions throughout the day. He appreciated a device that treatment monitoring facility,

The sensor measures every minute and generates a lot of data, so you can see trends. Health services may send a traffic light for advice. Ruth Gaspar said that information is useless without control and that it should be accompanied by diabetes education. There are two ways to get sensor data, from mobile or from reader. If mobile is used, the data is automatically uploaded to the query.

Integration in front of the patient is very easy. It’s the same app and it’s a new tab. are specific cases of patients who are already using the system and “they are happy“Because in the words of Ruth Gaspar, the system has come to provide them. There are data from other countries. Hypoglycemia is avoided, and there is better patient control, among other benefits,” stressed Dr. Javier Empudia. A memory of 800 records in. There are already 5,000 smart pens on the market. They last for five years.

Specifically, the integration of Abbott’s Flash Glucose Monitoring System and Novo Nordisk’s Novopen® 6 and Novopen Eco® Plus smart insulin pens. With this integration, people with insulin-dependent diabetes can get all the information they need to control their glucose in the FreeStyle LibreLink app. The app, available for iOS and Android, allows access to reports detailing glucose levels and insulin trends and dosages, allowing shared decision making based on valid and reliable data.

In addition to being a dose log screen viewer, information stored in the pen can be easily transferred to the app with a quick and easy scan. Thus, and taking a look at the history, it is easy to see when and how much insulin the patient has taken, up to a total of 800 injections. The system also discriminates between the actual dose and the dose made to check insulin flow, which seeks to eliminate potential air bubbles prior to administration. And all this information, together with glucose levels, can be shared with health professionals for optimal monitoring and control of diabetes.


Nation World News Desk
Nation World News Deskhttps://nationworldnews.com
Nation World News is the fastest emerging news website covering all the latest news, world’s top stories, science news entertainment sports cricket’s latest discoveries, new technology gadgets, politics news, and more.
Latest news
Related news


Please enter your comment!
Please enter your name here